Main menu

Pages

The European Medicines Agency warns against liquidity drugs to treat blood clots associated with the Corona vaccine


The European Medicines Agency (EMA) has issued new recommendations advising doctors not to use the blood-thinner heparin to treat rare blood clots and low platelets in people who have received the AstraZeneca or Johnson & Johnson (J&J) vaccine.


According to the “thehealthsite” report, in order to ensure appropriate treatment, the European Medicines Authority highlighted interim recommendations issued by the International Society of Thrombosis (ISTH) in April, which concluded that management should begin with non-heparin anticoagulants when vaccine-related thrombosis is suspected and low Platelets.


The European Medicines Agency's decision to emphasize the International Society of Thrombosis guidelines complies with recommendations from the FDA and the US Centers for Disease Control, which have issued strong warnings against the use of heparin in such conditions, claiming that it may make the disease worse.


According to the International Society of Thrombosis guidelines, clinicians should continue to use non-heparin anticoagulants and consider high-dose intravenous immunoglobulin once the coagulation status and vaccine-induced low platelet count are confirmed.


According to the European Economic Area Drug Regulator, 316 cases of uncommon blood clots with low platelets have been reported in individuals who received the AstraZeneca vaccine against COVID-19.


People have been reported to have had rare but serious blood clots after getting the AstraZeneca or J&J vaccine, and the AstraZeneca and J&J vaccines have been linked to an extremely uncommon thrombosis, a type of blood clot known as cerebral venous sinus thrombosis (CVST), which has been linked to a lower number of Thrombocytopenia or thrombocytopenia.


However, international drug regulators have also stressed that the benefits of corona vaccines outweigh the risks, as they continue to study allegations of rare, but potentially fatal blood clots, and companies have said cases are rare, and are investigating the occurrence of these rare events.


According to media reports, J&J said that no causal link has been found between vaccination and clots to date, and AstraZeneca, whose vaccine package contains a warning notice authorized by regulators, said it is investigating individual cases and potential mechanisms that could explain these rare events. Extremely.


What are blood clots?

A rare blood clot is known as thrombosis and, according to the European Medicines Agency (EMA), the majority of clots occur in the brain and abdomen, and according to the Centers for Disease Control and Prevention thrombotic episodes have been observed in several parts of the body, including the femoral vein, the internal jugular vein, and the The upper extremities and pulmonary artery, and this clot can block or stop blood flow in the affected area, as well as create major problems if it moves to a vital component of the circulatory system such as the brain or lungs.

Comments